GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Cosmos Health Inc (NAS:COSM) » Definitions » Valuation Rank

COSM (Cosmos Health) Valuation Rank


View and export this data going back to 2010. Start your Free Trial

What is Cosmos Health Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Cosmos Health Valuation Rank Related Terms

Thank you for viewing the detailed overview of Cosmos Health's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Cosmos Health Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Cosmos Health Inc (NAS:COSM) » Definitions » Valuation Rank
Comparable Companies
ENMI SNYR MCK COR CAH ASX:SIG SHSE:601607 HSIC HKSE:01099 SHSE:600332 MIL:AMP XSWX:GALE NZSE:EBO SHSE:600998 TSE:7459 SHSE:600511 PDCO TSE:2784 TSE:9987 SHSE:600739
Traded in Other Exchanges
V67A:Germany
Address
5 Agiou Georgiou Street, Thessaloniki, Thessaloniki, GRC, 55438
Website
https://www.cosmoshealthinc.com
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
Executives
Grigorios Siokas 10 percent owner 5 AG. GEORGIOU STR., PILEA, THESSALONIKI J3 TK57001
Georgios Terzis officer: Chief Financial Officer 2 MELITOS STR., NEA SMIRNI, ATTICA J3 17121
Suhel Bhutawala director 141 WEST JACKSON BOULEVARD, SUITE 4236, CHICAGO IL 60604
Nikolaos Bardakis officer: Chief Operating Officer 141 WEST JACKSON BOULEVARD, SUITE 4236, CHICAGO IL 60604
Manfred Ziegler director 141 WEST JACKSON BOULEVARD, SUITE 4236, CHICAGO IL 60604
Anastasios Aslidis director 11 CANTERBURY LANE, WATCHUNG NJ 07069
Pavlos Ignatiades officer: Chief Operating Officer KALAPATHAKI 5, PANORAMA, THESSALONIKI J3 55236
Peter Goldstein director 151 NORTH NOB HILL ROAD SUITE 321, FORT LAUDERDALE FL 33324
John James Hoidas director 9301 S. HARLEM AVENUE, OAK LAWN, CHICAGO IL 60453
Dimitrios Goulielmos director, 10 percent owner, officer: CEO 141 WEST JACKSON BLVD, SUITE 4236, CHICAGO IL 60604
Panagiotis Tolis director, officer: Secretary PERICLEOUS 50 STREET, ATHENS J3 15232
Panagiotis Drakopoulos director, 10 percent owner, officer: CEO 200 SOUTH WACKER DRIVE, SUITE 300, CHICAGO IL 60606
Vasileios Mavrogiannis director, 10 percent owner, officer: CFO TERTSETI 23 STREET, KESARIANI J3 16122